Emily Crossley

Chief Executive Officer at Duchenne UK

51 year

Miscellaneous

Health Technology

Profile

Emily Crossley is the founder of Duchenne UK, which is founded in 2012, where she currently holds the title of Joint Chief Executive Officer.
She is also currently a Director at Duchenne Research (UK) Investment Ltd.

Emily Crossley active positions

Companies	Position	Start
Duchenne UK Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012.	Chief Executive Officer	01/01/2012
Duchenne Research (UK) Investment Ltd. Duchenne Research (UK) Investment Ltd. BiotechnologyHealth Technology Duchenne Research (UK) Investment Ltd. is a biotechnology research and British experimental development company founded in 2014. The location of the private company is not specified. The company provides services in the field of biotechnology research and development.	Director/Board Member	05/01/2016

All active positions of Emily Crossley

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Emily Crossley's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Duchenne UK Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012.	Miscellaneous
Duchenne Research (UK) Investment Ltd. Duchenne Research (UK) Investment Ltd. BiotechnologyHealth Technology Duchenne Research (UK) Investment Ltd. is a biotechnology research and British experimental development company founded in 2014. The location of the private company is not specified. The company provides services in the field of biotechnology research and development.	Health Technology